- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity
Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Transcript
What are the outcomes of the safety and effectiveness of alirocumab by race and ethnicity and how do these results help clinicians?
Throughout the Praluent development program, before and after approval, we’ve seen uniform excellent efficacy and safety in all the patient populations that we’ve studied. Here, we’re talking about race and ethnicity. We’ve looked across the board, including our recent results that we unveiled with diabetes, showing the great ability of Praluent to really get patients down to their LDL target goals in a safe and effective way.
How does the combination of results on race and ethnicity and in patients with diabetes and dyslipidemia help clinicians in clinical practice?
Those results, plus all the other results that we’ve seen in the ODYSSEY program, really provide a great data set for physicians when they’re treating their patient. Knowing that if they want to get their patients down to lower LDL targets, regardless of where they want to go, that Praluent can actually provide that really robust LDL lowering in a safe and effective way, regardless of who the patients are.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
